Sarepta Therapeutics,, Inc. Common Stock

Sarepta's 28.77% short interest stands as a significant outlier—nearly triple the pharma sector average—suggesting deep skepticism about the company's pipeline execution or commercial trajectory. Trading at $2.1B market cap with no profitable earnings (n/a P/E) and an RSI of 41.8 indicates the stock has room to run either direction from a technical standpoint, though the combination of high short positioning and pre-profitability status creates potential squeeze dynamics if clinical or regulatory catalysts materialize. The elevated short ratio relative to fundamentals worth watching closely.